Data / Drug companies / Octreotide acetate
Octreotide acetate: 11 companies and 42 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Octreotide acetate is listed in the FDA National Drug Code Directory by 11 companies, with 42 products in commercial distribution. 35 of the products (83.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; kit; injection, and the newest product started marketing on January 28, 2026.
The request: Get every company that lists octreotide acetate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 42
- Generic (ANDA) products
- 35 (83.3%)
- Application numbers
- 16
- Routes
- Intravenous, Subcutaneous, Intramuscular
- Brand names
- Octreotide, Sandostatin Lar Depot, Sandostatin, Bynfezia Pen
- openFDA record search
- api.fda.gov
Companies that list octreotide acetate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 6 | injection, solution | Generic drugs (ANDA) | March 14, 2006 |
| Mylan Institutional LLC | 6 | kit; injection, solution | Generic drugs (ANDA) | January 28, 2026 |
| Novartis Pharmaceuticals Corporation | 6 | kit; injection, solution | New drug applications (NDA) | July 22, 2016 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 5 | injection, solution | Generic drugs (ANDA) | May 25, 2022 |
| Hikma Pharmaceuticals USA Inc. | 5 | injection, solution | Generic drugs (ANDA) | April 8, 2005 |
| Gland Pharma Limited | 4 | injection, solution | Generic drugs (ANDA) | June 22, 2023 |
| Meitheal Pharmaceuticals Inc. | 3 | injection, solution | Generic drugs (ANDA) | February 28, 2025 |
| Teva Pharmaceuticals, Inc. | 3 | kit | Generic drugs (ANDA) | March 20, 2025 |
| Glenmark Pharmaceuticals Inc., USA | 2 | injection, solution | Generic drugs (ANDA) | August 9, 2023 |
| Hainan Shuangcheng Pharmaceuticals Co., Ltd. | 1 | injection, solution | Generic drugs (ANDA) | May 2, 2024 |
| Sun Pharmaceutical Industries, Inc. | 1 | injection | New drug applications (NDA) | February 24, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 32 | 76.2% |
| Kit | 9 | 21.4% |
| Injection | 1 | 2.4% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 35 | 83.3% |
| New drug applications (NDA) | 7 | 16.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Somatostatin Analog | 33 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.